Home > Haematological Malignancies > Myelodysplastic Syndromes
    Content Type:
  • Myelodysplastic Syndromes


    An Introduction to Myelodysplastic Syndromes

    Myelodysplastic syndromes include a range of bone marrow malignancies characterised by cytopenia and ineffective haematopoiesis, resulting in chronic anaemia and the risk of progression to acute myeloid leukaemia. The current standard of care ranges from supportive care to allogeneic stem cell transplant until recently, progress had lagged behind other blood cancers, with no new approved therapies in over a decade. However, in July 2020 the FDA approved the first oral treatment, a fixed-dose combination of the hypomethylating agent decitabine and the cytidine deaminase inhibitor cedazuridine. Luspatercept-aamt has also recently been approved for treatments in patients with anaemia who require red blood cell transfusions and have not achieved success with an erythropoiesis-stimulating agent.

    Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever-changing landscape.

    Our supporting partners do not constitute an endorsement of the content on this page.

    Myelodysplastic Syndromes Content

    Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar